Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)

MLA

Ludwig Heesen, et al. “Abstract CT221: Mutanome Engineered RNA Immuno-Therapy (MERIT) for Patients with Triple Negative Breast Cancer (TNBC).” Cancer Research, vol. 79, July 2019, p. CT221. EBSCOhost, https://doi.org/10.1158/1538-7445.am2019-ct221.

APA

Ludwig Heesen, Katrin Frenzel, Stefanie Bolte, Valesca Bukur, Mustafa Diken, Evelyna Derhovanessian, Sebastian Kreiter, Andreas N. Kuhn, Klaus Kühlcke, Martin Löwer, Henrik Lindman, Steve Pascolo, Marcus Schmidt, Andreas Schneeweiss, Tobias Sjöblom, Kris Thielemans, Laurence Zitvogel, Özlem Türeci, & Ugur Sahin. (2019). Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). Cancer Research, 79, CT221. https://doi.org/10.1158/1538-7445.am2019-ct221

Chicago

Ludwig Heesen, Katrin Frenzel, Stefanie Bolte, Valesca Bukur, Mustafa Diken, Evelyna Derhovanessian, Sebastian Kreiter, et al. 2019. “Abstract CT221: Mutanome Engineered RNA Immuno-Therapy (MERIT) for Patients with Triple Negative Breast Cancer (TNBC).” Cancer Research 79 (July): CT221. doi:10.1158/1538-7445.am2019-ct221.